NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

Tatva Chintan Pharma Chem : Q4 2024 Quarterly Earnings: YoY Sales Down 21.08 %, QoQ Up 16.7. %

May 13, 2024May 13, 2024| adminadmin| 0 Comments| 10:00 am
Image is loading
Categories:

Share the post "Tatva Chintan Pharma Chem : Q4 2024 Quarterly Earnings: YoY Sales Down 21.08 %, QoQ Up 16.7. %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company’s sales declined by -21.08 % over the year, substantial increase in net sales/revenue by 16.7 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 438.1 %. Marginal increase in other income during this quarter, up by 270.49%.
  • Profit over the Year and quarter: Challenges in sustaining profitability for Tatva Chintan Pharma Chem Limited. Profit dropped by -43.29 % Year to Year, Tatva Chintan Pharma Chem Limited’s profitability increased by 178.26 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -46.27 % Year to Year. EPS increased by 177.7 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Tatva Chintan Pharma Chem Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 124.511 Cr Rs. 84.206 Cr Rs. 98.266 Cr + 16.7 % -21.08 %
Expenses Rs. 108.24 Cr Rs. 73.21 Cr Rs. 82.66 Cr + 12.91 % -23.63 %
Operating Profit Rs. 16.27 Cr Rs. 11 Cr Rs. 15.61 Cr + 41.91 % -4.06 %
OPM % 13.07 % 13.06 % 15.89 % + 2.83 % + 2.82 %
Other Income Rs. 0.84 Cr Rs. 1.22 Cr Rs. 4.52 Cr + 270.49 % + 438.1 %
Interest Rs. 3.2 Cr Rs. 0.38 Cr Rs. 0.21 Cr -44.74 % -93.44 %
Depreciation Rs. 2.53 Cr Rs. 6.58 Cr Rs. 6.23 Cr -5.32 % + 146.25 %
Profit before tax Rs. 11.38 Cr Rs. 5.26 Cr Rs. 13.69 Cr + 160.27 % + 20.3 %
Tax % 117.3 % 34.12 % 29.77 % -4.35 % -87.53 %
Net Profit Rs. 16.95 Cr Rs. 3.46 Cr Rs. 9.61 Cr + 177.75 % -43.3 %
EPS in Rs Rs. 7.65 Rs. 1.48 Rs. 4.11 + 177.7 % -46.27 %


Today, we’re looking at Tatva Chintan Pharma Chem Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -21.08 %. However, it did see a marginal increase of 16.7 % from the previous quarter. Expenses ticked up slightly by 12.91 % quarter-on-quarter, aligning with the annual decline of -23.63 %. Operating profit, while down -4.06 % compared to last year, faced a quarter-on-quarter increase of 41.91 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.82 %, but an expansion of 2.83 % sequentially. Other income rose by 270.49 % compared to the last quarter, despite an annual growth of 438.1 %. Interest expenses dropped significantly by -44.74 % from the previous quarter, yet the year-over-year decrease remains at a moderate -93.44 %. Depreciation costs fell by -5.32 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 146.25 %. Profit before tax grew annually by 20.3 % but saw an increase from the preceding quarter by 160.27 %.
Tax expenses as a percentage of profits decreased slightly by -87.53 % compared to last year, with a more notable quarter-on-quarter decrease of -4.35 %. Net profit fell by -43.3 % year-on-year but experienced a 177.75 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -46.27 % but a quarterly rise of 177.7 %. In summary, Tatva Chintan Pharma Chem Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 124.511 Cr Rs. 84.206 Cr Rs. 98.266 Cr + 16.7 % -21.08 %
Expenses Rs. 108.24 Cr Rs. 73.21 Cr Rs. 82.66 Cr + 12.91 % -23.63 %
Operating Profit Rs. 16.27 Cr Rs. 11 Cr Rs. 15.61 Cr + 41.91 % -4.06 %
Net Profit Rs. 16.95 Cr Rs. 3.46 Cr Rs. 9.61 Cr + 177.75 % -43.3 %
EPS in Rs Rs. 7.65 Rs. 1.48 Rs. 4.11 + 177.7 % -46.27 %


In reviewing Tatva Chintan Pharma Chem Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -21.08 % year-on-year, however, there was a minor increase of 16.7 % from the previous quarter. Expenses decreased by -23.63 % compared to the previous year, with a 12.91 % increase quarter-on-quarter. Operating Profit dropped by -4.06 % annually, and saw a 41.91 % increase from the last quarter.
Net Profit showed yearly decrease of -43.3 %, and experienced a 177.75 % increase from the previous quarter. Earnings Per Share (EPS) fell by -46.27 % annually, however rose by 177.7 % compared to the last quarter. In essence, while Tatva Chintan Pharma Chem Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Tatva Chintan Pharma Chem “]

Related Post